Assessing Dynavax Technologies: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
Dynavax Technologies (NASDAQ:DVAX) has been analyzed by 4 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $25.5, down 4.67% from the previous $26.75. Key analysts include Paul Choi from Goldman Sachs, who lowered his target to $15.00, and Edward White from HC Wainwright & Co., who maintained a $29.00 target. Dynavax has shown positive revenue growth and strong financial performance, but its debt-to-equity ratio is higher than the industry average.
August 08, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Dynavax Technologies has received mixed analyst ratings with an average 12-month price target of $25.5, a decrease from the previous $26.75. Key analysts include Paul Choi from Goldman Sachs, who lowered his target to $15.00, and Edward White from HC Wainwright & Co., who maintained a $29.00 target. The company has shown positive revenue growth and strong financial performance, but its debt-to-equity ratio is higher than the industry average.
The mixed analyst ratings and the slight decrease in the average price target suggest a neutral short-term impact on DVAX's stock price. While the company shows strong financial performance, the higher debt-to-equity ratio and the lowered price target by a key analyst balance out the positive aspects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100